Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole

BMC Gastroenterology

Volumn 8, Issue , 2008, Pages

  Wilcox, C Mel ^a   Martin, Toni ^a   Phadnis, Milind ^a   Mohnen, Jean ^a   Worthington, Julie ^b   Hirschowitz, Basil I ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN; GASTRIN; LANSOPRAZOLE; MACROLIDE; METRONIDAZOLE; OMEPRAZOLE; PENICILLIN G; PENTAGASTRIN; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFANILAMIDE DERIVATIVE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIINFECTIVE AGENT; ANTIULCER AGENT;

ADULT; ANEMIA; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; GASTROINTESTINAL INFECTION; GOUT; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INFECTION; LIVER DYSFUNCTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEPHROLITHIASIS; PATIENT MONITORING; PRESCRIPTION; STOMACH ACID SECRETION; STOMACH ANTRUM RESECTION; STOMACH PH; TREATMENT DURATION; TREATMENT OUTCOME; ZOLLINGER ELLISON SYNDROME; AGED; CLOSTRIDIUM DIFFICILE; COHORT ANALYSIS; DOSE RESPONSE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; INCIDENCE; LONGITUDINAL STUDY; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; PH; PROSPECTIVE STUDY; PSEUDOMEMBRANOUS COLITIS; SECRETION; STOMACH ACID;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; CLOSTRIDIUM DIFFICILE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; FOLLOW-UP STUDIES; GASTRIC ACID; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; HYDROGEN-ION CONCENTRATION; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; ZOLLINGER-ELLISON SYNDROME;

EID: 44949232094     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-8-18     Document Type: Article

References (17)

1. Rodríguez LAG Ruigómez A Panés J Use of acid-suppressing drugs and the risk of bacterial gastroenteritis Clin Gastroenterol Hepatol 2007, 5:1418-1423 10.1016/j.cgh.2007.09.010 18054750
2. Canani RB Cirillo P Roggero P Romano C Malamisura B Terrin G Passariello A Manguso F Morelli L Guarino A for the Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP) Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children Pediatrics 2006, 117:e817-e820 10.1542/peds.2005-1655 16651285
3. Dial S Delaney JAC Barkun AN Suissa S Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile - associated disease JAMA 2005, 294:2989-2995 10.1001/jama.294.23.2989 16414946
4. Yearsley KA Gilby LJ Ramadas AV Kubiak EM Fone DL Allison MC Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhea Aliment Pharmacol Ther 2006, 24:613-619 10.1111/ j.1365-2036.2006.03015.x 16907893
5. Hirschowitz BI Simmons J Mohnen J Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: A 13-year prospective study Clin Gastroenterol Hepatol 2005, 3:39-48 10.1016/S1542-3565(04)00606-8 15645403
6. Halter F Keller M A comparison between intragastric titration and aspiration technique under basal conditions and after food or pentagastrin stimulation Am J Dig Dis 1978, 23:723-9 10.1007/BF01072360 685941
7. Hirschowitz BI Groarke J Vagal effects on acid and pepsin secretion and serum gastrin in duodenal ulcer and controls Dig Dis Sci 1993, 38:1874-84 10.1007/BF01296112 8404408
8. Hirschowitz BI Keeling D Lewin M Okabe S Parsons M Sewing K Pharmacological aspects of acid secretion Dig Dis Sci 1995, 49(2 Suppl):3S-23S 10.1007/BF02214869
9. Pépin J Saheb N Coulombe MA Alary ME Corriveau MP Authier S Leblanc M Rivard G Bettez M Primeau V Nguyen M Jacob CE Lantheir L Emergence of Fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: A cohort study during an epidemic in Quebec Clin Infect Dis 2005, 41:1254-60 10.1086/496986 16206099
10. Shah S Lewis A Leopold D Dunstan F Woodhouse K Gastric acid suppression does not promote clostridial diarrhea in the elderly Q J Med 2000, 93:175-181
11. Lowe DO Mamdani MM Kopp A Low DE Juurlink DN Proton pump inhibitors and hospitalization for Clostridium difficile - associated disease: A population-based study Clin Infect Dis 2006, 43:1272-6 10.1086/508453 17051491
12. Giannella RA Broitman SA Zamcheck N Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective Ann Intern Med 1973, 78:271-276 4567180
13. Cook GC Infective gastroenteritis and its relationship to reduced gastric acidity Scand J Gastroenterol Suppl 1985, 111:17-23 10.3109/ 00365528509093751 3925541
14. Harder H Teyssen S Stephan F Pfützer R Kiel G Fuchs W Singer MV Effect of 7-day therapy with different doses of the proton pump inhibitor lansoprazole on the intragastric pH in healthy human subjects Scand J Gastroenterol 1999, 34:551-61 10.1080/003655299750025994 10440603
15. Miner P Katz PO Chen Y Sostek M Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five-way crossover study Am J Gastroenterol 2003, 98:2616-2620 10.1111/ j.1572-0241.2003.08783.x 14687806
16. Katz PO Hatlebakk JG Castell DO Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole Aliment Pharmacol Ther 2000, 14:709-714 10.1046/j.1365-2036.2000.00775.x 10848653
17. Wilder-Smith CH Röhss K Nilsson-Pieschl C Junghard O Nyman L Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers Digestion 2003, 68:184-188 10.1159/000075697 14691345